Financial help and assistance navigator
Where the money can come from. OnCo records access and cost information on 95 products: manufacturer assistance programmes, reimbursement decisions and whether a generic exists, country by country. This page gathers all of it in one place, adds the national schemes and charities that pay for care or living costs in each country, and the patient organisations that run copay and travel funds. Filter to your country and your treatments, then print the list.
Country follows the region switcher in the header; products are seeded from the treatments in your browser profile. Nothing leaves your device. Print gives a one-page list to take to a social worker or financial navigator.
Financial help checklist: all countries
Printed from onco.cc/assistance/ on 2026-09-10. Verify every programme at its own site before relying on it.
Per-product help in all countries
From each product's access record; blank means not recorded, not that nothing exists.| Product | Country | Manufacturer programme | Reimbursement | List price | Generic | Source |
|---|---|---|---|---|---|---|
| Abemaciclib Small-molecule CDK4/6 inhibitor | United Kingdom | Not recorded | NICE: recommended with fulvestrant (TA579), aromatase inhibitor (TA563), and adjuvant (TA810) | Not recorded | Not recorded | source as of 2026-09-06 |
| Abemaciclib Small-molecule CDK4/6 inhibitor | United States | lillycares.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Actinium-225 DOTATATE Targeted alpha therapy | United States | Not recorded | Investigational | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Actinium-225 PSMA agents Targeted alpha therapy | Germany | Not recorded | Compassionate use at selected centres (Heidelberg and others) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Actinium-225 PSMA agents Targeted alpha therapy | United States | Not recorded | Investigational (phase 3) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Adagrasib Small-molecule inhibitor (KRAS G12C) | United Kingdom | Not recorded | NICE: appraisal for KRAS G12C NSCLC (2025) | Not recorded | Not recorded | source as of 2026-09-06 |
| Adagrasib Small-molecule inhibitor (KRAS G12C) | United States | bmsaccesssupport.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Afamitresgene autoleucel TCR-T (MAGE-A4) | United States | Not recorded | Medicare Part B (inpatient/outpatient); commercial per plan | $727,000 per infusion (list price at launch, 2024) | Not recorded | Not recorded as of 2026-09-06 |
| AK146D1 Bispecific ADC | China | Not recorded | Investigational | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Amivantamab Bispecific antibody (EGFR×MET) | United Kingdom | Not recorded | NICE: recommended with lazertinib for untreated EGFR-mutant NSCLC (2025) and exon 20 insertion after platinum | Not recorded | Not recorded | source as of 2026-09-06 |
| Amivantamab Bispecific antibody (EGFR×MET) | United States | janssencarepath.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| ArteraAI Breast AI digital pathology risk test | United States | Not recorded | Launched May 2026; coverage determinations pending | Not recorded | Not recorded | source as of 2026-09-06 |
| ArteraAI Prostate AI digital pathology prognostic/predictive test | United States | Not recorded | Medicare coverage via MolDX; NCCN-listed | ~$1,500 (Medicare CLFS rate established 2025, approximate) | Not recorded | source as of 2026-09-06 |
| Atezolizumab Monoclonal antibody (anti-PD-L1) | United Kingdom | Not recorded | NICE: recommended in NSCLC (several TAs), SCLC with chemotherapy, HCC with bevacizumab, adjuvant NSCLC | Not recorded | Not recorded | source as of 2026-09-06 |
| Atezolizumab Monoclonal antibody (anti-PD-L1) | United States | genentech-access.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Autogene cevumeran Personalised mRNA neoantigen vaccine | United States | Not recorded | Investigational (phase 2 IMCODE003) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Axicabtagene ciloleucel CAR-T (CD19) | United Kingdom | Not recorded | NICE: recommended for relapsed/refractory DLBCL after ≥2 therapies (TA872) and second-line early relapse (TA895) | Not recorded | Not recorded | source as of 2026-09-06 |
| Axicabtagene ciloleucel CAR-T (CD19) | United States | kitekonnect.com | Medicare Part B (physician-administered); commercial plans per formulary | $373,000 per infusion (list price at launch 2017; higher today) | Not recorded | source as of 2026-09-06 |
| Belantamab mafodotin ADC | United Kingdom | Not recorded | NICE: recommended in combination regimens for relapsed myeloma (2025) | Not recorded | Not recorded | source as of 2026-09-06 |
| Belantamab mafodotin ADC | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Belzutifan Small-molecule HIF-2α inhibitor | United Kingdom | Not recorded | NICE: appraisal for RCC after IO and VEGF-TKI (2025-26) | Not recorded | Not recorded | source as of 2026-09-06 |
| Belzutifan Small-molecule HIF-2α inhibitor | United States | merckaccessprogram-welireg.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Blinatumomab Bispecific T-cell engager (CD19×CD3) | United Kingdom | Not recorded | NICE: recommended in Ph-negative relapsed/refractory B-ALL (TA450) and MRD-positive ALL (TA589) | Not recorded | Not recorded | source as of 2026-09-06 |
| Blinatumomab Bispecific T-cell engager (CD19×CD3) | United States | amgensupportplus.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Brentuximab vedotin ADC | United Kingdom | Not recorded | NICE: recommended in CD30+ Hodgkin lymphoma settings (TA446, TA524) and first-line stage IV with AVD | Not recorded | Not recorded | source as of 2026-09-06 |
| Brentuximab vedotin ADC | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Capivasertib Small-molecule AKT inhibitor | United Kingdom | Not recorded | NICE: recommended with fulvestrant for PIK3CA/AKT1/PTEN-altered HR+ breast cancer (TA998) | Not recorded | Not recorded | source as of 2026-09-06 |
| Capivasertib Small-molecule AKT inhibitor | United States | astrazeneca-us.com/medicines/access-360 | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Carboplatin Cytotoxic chemotherapy (platinum) | United Kingdom | Not recorded | NHS standard; generic | Not recorded | Yes | Not recorded as of 2026-09-06 |
| Carboplatin Cytotoxic chemotherapy (platinum) | United States | Not recorded | Medicare Part B; generic | Not recorded | Yes | source as of 2026-09-06 |
| Cemiplimab Monoclonal antibody (anti-PD-1) | United Kingdom | Not recorded | NICE: recommended for advanced cutaneous squamous cell carcinoma (TA592) and PD-L1 ≥50% NSCLC | Not recorded | Not recorded | source as of 2026-09-06 |
| Cemiplimab Monoclonal antibody (anti-PD-1) | United States | libtayosurroundcare.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Ciltacabtagene autoleucel CAR-T (BCMA) | United Kingdom | Not recorded | NICE: recommended for relapsed myeloma after ≥1 line, lenalidomide-refractory (2025) | Not recorded | Not recorded | source as of 2026-09-06 |
| Ciltacabtagene autoleucel CAR-T (BCMA) | United States | janssencarepath.com | Medicare Part B (physician-administered); commercial plans per formulary | $465,000 per infusion (list price at launch, 2022; 2026 list higher) | Not recorded | source as of 2026-09-06 |
| Daraxonrasib Small-molecule pan-RAS(ON) inhibitor | United States | Not recorded | Investigational; NDA expected after RASolute 302 | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Datopotamab deruxtecan ADC | United Kingdom | Not recorded | NICE: appraisal in progress for HR+/HER2- breast cancer; not yet recommended (2026) | Not recorded | Not recorded | source as of 2026-09-06 |
| Datopotamab deruxtecan ADC | United States | datroway.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Disitamab vedotin ADC | China | Not recorded | NMPA approved 2021; on the National Reimbursement Drug List | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Disitamab vedotin ADC | United States | Not recorded | Investigational (Pfizer; phase 3 in urothelial cancer) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Dostarlimab Monoclonal antibody (anti-PD-1) | United Kingdom | Not recorded | NICE: recommended with chemotherapy for dMMR/MSI-H advanced endometrial cancer (TA1068) | Not recorded | Not recorded | source as of 2026-09-06 |
| Dostarlimab Monoclonal antibody (anti-PD-1) | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Doxorubicin Cytotoxic chemotherapy (anthracycline) | United States | Not recorded | Not recorded | Generic; low cost | Yes | Not recorded as of 2026-09-07 |
| Durvalumab Monoclonal antibody (anti-PD-L1) | United Kingdom | Not recorded | NICE: recommended after chemoradiation in stage III NSCLC (TA798), biliary tract cancer, limited-stage SCLC, perioperative bladder and gastric cancer | Not recorded | Not recorded | source as of 2026-09-06 |
| Durvalumab Monoclonal antibody (anti-PD-L1) | United States | astrazeneca-us.com/medicines/access-360 | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Elacestrant Oral SERD | United Kingdom | Not recorded | NICE: recommended for ESR1-mutated ER+/HER2- advanced breast cancer (2024) | Not recorded | Not recorded | source as of 2026-09-06 |
| Elacestrant Oral SERD | United States | Not recorded | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Encorafenib Small-molecule kinase inhibitor (BRAF) | United Kingdom | Not recorded | NICE: recommended with binimetinib in BRAF V600 melanoma (TA562) and with cetuximab in BRAF V600E CRC (TA668) | Not recorded | Not recorded | source as of 2026-09-06 |
| Encorafenib Small-molecule kinase inhibitor (BRAF) | United States | pfizeroncologytogether.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Enfortumab vedotin ADC | European Union | Not recorded | EMA approved 2022 (monotherapy), 2024 (with pembrolizumab) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Enfortumab vedotin ADC | United Kingdom | Not recorded | NICE: recommended with pembrolizumab for untreated advanced urothelial cancer (2024) | Not recorded | Not recorded | source as of 2026-09-06 |
| Enfortumab vedotin ADC | United States | padcev.com/support | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| FAP-2286 (177Lu / 68Ga) Theranostic pair (peptide radioligand) | United States | Not recorded | Investigational | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| FoundationOne CDx / Liquid CDx Comprehensive genomic profiling test | United States | Not recorded | Medicare national coverage for FDA-approved CGP in advanced cancer (NCD 90.2); commercial coverage broad | ~$3,500 (Medicare CLFS rate for FoundationOne CDx) | Not recorded | source as of 2026-09-06 |
| Galleri Multi-cancer early detection blood test | United Kingdom | Not recorded | Not available on the NHS; trial access via NHS-Galleri | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Galleri Multi-cancer early detection blood test | United States | Not recorded | Not covered by Medicare (pending FDA decision and the MCED Screening Coverage Act); some employer and Medicare Advantage programmes cover | $949 self-pay (GRAIL list price) | Not recorded | source as of 2026-09-06 |
| Gedatolisib Small-molecule pan-PI3K/mTOR inhibitor | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Gemtuzumab ozogamicin ADC | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Glofitamab Bispecific T-cell engager (CD20×CD3, 2:1) | United Kingdom | Not recorded | NICE: recommended for relapsed/refractory DLBCL after ≥2 therapies (TA927) | Not recorded | Not recorded | source as of 2026-09-06 |
| Glofitamab Bispecific T-cell engager (CD20×CD3, 2:1) | United States | genentech-access.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Ifinatamab deruxtecan ADC | United States | Not recorded | Investigational (phase 3 IDeate-Lung02) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Imatinib Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA) | United Kingdom | Not recorded | NHS standard; generic | Not recorded | Yes | Not recorded as of 2026-09-06 |
| Imatinib Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA) | United States | Not recorded | Medicare Part D; generic since 2016 (list price fell >90%) | Not recorded | Yes | source as of 2026-09-06 |
| Inavolisib Small-molecule PI3Kα inhibitor and degrader | United Kingdom | Not recorded | NICE: appraisal for PIK3CA-mutant HR+ breast cancer (2025-26) | Not recorded | Not recorded | source as of 2026-09-06 |
| Inavolisib Small-molecule PI3Kα inhibitor and degrader | United States | genentech-access.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Intismeran autogene Personalised mRNA neoantigen vaccine | United States | Not recorded | Investigational; BLA expected 2026-27 after INTerpath-001 | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Ipilimumab Monoclonal antibody (anti-CTLA-4) | United Kingdom | Not recorded | NICE: recommended with nivolumab in melanoma, RCC, MSI-H CRC, mesothelioma, HCC | Not recorded | Not recorded | source as of 2026-09-06 |
| Ipilimumab Monoclonal antibody (anti-CTLA-4) | United States | bmsaccesssupport.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Ivonescimab Bispecific antibody (PD-1×VEGF) | China | Not recorded | NMPA approved 2024; NRDL inclusion 2025 | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Ivonescimab Bispecific antibody (PD-1×VEGF) | United States | Not recorded | Investigational; BLA under review (PDUFA 14 November 2026) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Izalontamab brengitecan Bispecific ADC | China | Not recorded | NMPA filings under review (2026) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Izalontamab brengitecan Bispecific ADC | United States | Not recorded | Investigational; BMS filing expected after BL-B01D1-307 | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Lenalidomide Immunomodulatory drug (cereblon E3 ligase modulator) | United States | Not recorded | Not recorded | ~$20,000 per month (brand, 2022); generics volume-limited until 2026 | Yes | Not recorded as of 2026-09-07 |
| Lifileucel TIL cell therapy | European Union | Not recorded | EMA approved 2025; national pricing pending | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Lifileucel TIL cell therapy | United States | iovancecares.com | Medicare Part B (physician-administered); commercial plans per formulary | $515,000 per treatment (list price at launch, 2024) | Not recorded | source as of 2026-09-06 |
| Loncastuximab tesirine ADC | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Lorlatinib Small-molecule kinase inhibitor (ALK/ROS1) | United Kingdom | Not recorded | NICE: recommended first-line for ALK+ NSCLC (TA909) | Not recorded | Not recorded | source as of 2026-09-06 |
| Lorlatinib Small-molecule kinase inhibitor (ALK/ROS1) | United States | pfizeroncologytogether.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Lutetium-177 dotatate Radioligand therapy (beta) | United Kingdom | Not recorded | NICE: recommended for unresectable/metastatic GEP-NETs (TA539) | Not recorded | Not recorded | source as of 2026-09-06 |
| Lutetium-177 dotatate Radioligand therapy (beta) | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | ~$47,500 per dose (launch price 2018) | Not recorded | source as of 2026-09-06 |
| Lutetium-177 vipivotide tetraxetan Radioligand therapy (beta) | United Kingdom | Not recorded | NICE: recommended for PSMA+ mCRPC after ARPI and taxane (2025); pre-chemotherapy appraisal in progress | Not recorded | Not recorded | source as of 2026-09-06 |
| Lutetium-177 vipivotide tetraxetan Radioligand therapy (beta) | United States | novartis.com/us-en/patient-support | Medicare Part B (physician-administered); commercial plans per formulary | ~$42,500 per dose (Novartis, 2022 launch price) | Not recorded | source as of 2026-09-06 |
| Mirvetuximab soravtansine ADC | United Kingdom | Not recorded | NICE: recommended for FRα-high platinum-resistant ovarian cancer (2025) | Not recorded | Not recorded | source as of 2026-09-06 |
| Mirvetuximab soravtansine ADC | United States | elahere.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Niraparib Small-molecule PARP inhibitor | United Kingdom | Not recorded | NICE: recommended for ovarian maintenance (TA528, TA673) and with abiraterone in BRCA-mutant prostate cancer (Akeega) | Not recorded | Not recorded | source as of 2026-09-06 |
| Niraparib Small-molecule PARP inhibitor | United States | Not recorded | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Nivolumab Monoclonal antibody (anti-PD-1) | United Kingdom | Not recorded | NICE: recommended across melanoma, NSCLC, RCC, Hodgkin, HNSCC, gastric/oesophageal, urothelial, MSI-H CRC indications | Not recorded | Not recorded | source as of 2026-09-06 |
| Nivolumab Monoclonal antibody (anti-PD-1) | United States | bmsaccesssupport.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Olaparib Small-molecule PARP inhibitor | European Union | Not recorded | EMA approved across indications | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Olaparib Small-molecule PARP inhibitor | United Kingdom | Not recorded | NICE: recommended in ovarian maintenance (TA598, TA620), adjuvant gBRCA breast (TA886), metastatic breast (TA1100), prostate (TA887) | Not recorded | Not recorded | source as of 2026-09-06 |
| Olaparib Small-molecule PARP inhibitor | United States | astrazeneca-us.com/medicines/access-360 | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Oncotype DX Gene-expression prognostic/predictive assay | United Kingdom | Not recorded | NICE: recommended for ER+/HER2- node-negative and some node-positive early breast cancer (DG58) | Not recorded | Not recorded | source as of 2026-09-06 |
| Oncotype DX Gene-expression prognostic/predictive assay | United States | Not recorded | Medicare and most commercial plans for node-negative and node-positive (1-3) HR+/HER2- early breast cancer | ~$4,500 list price | Not recorded | source as of 2026-09-06 |
| Optune / Optune Pax (TTFields) Device (tumour treating fields) | United Kingdom | Not recorded | NICE: not recommended for glioblastoma (2018 assessment); reassessment pending | Not recorded | Not recorded | source as of 2026-09-06 |
| Optune / Optune Pax (TTFields) Device (tumour treating fields) | United States | Not recorded | Medicare covers Optune Gio for newly diagnosed glioblastoma (LCD); Optune Lua and Pax coverage evolving | ~$21,000 per month rental (Novocure disclosed pricing, US) | Not recorded | Not recorded as of 2026-09-06 |
| Osimertinib Small-molecule kinase inhibitor (EGFR) | China | Not recorded | NRDL listed since 2019 with major price cut | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Osimertinib Small-molecule kinase inhibitor (EGFR) | United Kingdom | Not recorded | NICE: recommended first-line (TA654), adjuvant (TA761), and after chemoradiation | Not recorded | Not recorded | source as of 2026-09-06 |
| Osimertinib Small-molecule kinase inhibitor (EGFR) | United States | astrazeneca-us.com/medicines/access-360 | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Paclitaxel / nab-paclitaxel Cytotoxic chemotherapy (taxane) | United Kingdom | Not recorded | NHS standard; generic | Not recorded | Yes | Not recorded as of 2026-09-06 |
| Paclitaxel / nab-paclitaxel Cytotoxic chemotherapy (taxane) | United States | Not recorded | Medicare Part B; generic paclitaxel and nab-paclitaxel available | Not recorded | Yes | source as of 2026-09-06 |
| Palbociclib Small-molecule CDK4/6 inhibitor | United Kingdom | Not recorded | NICE: recommended with aromatase inhibitor (TA495) and fulvestrant (TA619) | Not recorded | Not recorded | source as of 2026-09-06 |
| Palbociclib Small-molecule CDK4/6 inhibitor | United States | pfizeroncologytogether.com | Medicare Part D; generic entry expected 2027 in the US | Not recorded | No | source as of 2026-09-06 |
| Patritumab deruxtecan ADC | United States | Not recorded | Investigational; BLA withdrawn May 2025 after HERTHENA-Lung02 OS result | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Pembrolizumab Monoclonal antibody (anti-PD-1) | European Union | Not recorded | EMA approved; reimbursed in all member states for core indications | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Pembrolizumab Monoclonal antibody (anti-PD-1) | United Kingdom | Not recorded | NICE: recommended across many indications (melanoma, NSCLC, TNBC KEYNOTE-522/355, RCC, HNSCC, cervical, oesophageal and others) | Not recorded | Not recorded | source as of 2026-09-06 |
| Pembrolizumab Monoclonal antibody (anti-PD-1) | United States | merckaccessprogram-keytruda.com | Medicare Part B (physician-administered); commercial plans per formulary | $11,564 per 200 mg dose (WAC, Merck price disclosure 2024) | Not recorded | source as of 2026-09-06 |
| Piflufolastat F-18 / Pylarify TruVu PET imaging agent | United States | Not recorded | Medicare pass-through/payment for PSMA PET; broad commercial coverage for staging and biochemical recurrence | Not recorded | Not recorded | source as of 2026-09-06 |
| Puxitatug samrotecan ADC | United States | Not recorded | Investigational | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Raludotatug deruxtecan ADC | United States | Not recorded | Investigational (REJOICE-Ovarian01) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Relacorilant Small-molecule glucocorticoid receptor antagonist | United States | Not recorded | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Relatlimab + nivolumab Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1) | United Kingdom | Not recorded | NICE: recommended for untreated advanced melanoma, PD-L1 <1% (2024) | Not recorded | Not recorded | source as of 2026-09-06 |
| Relatlimab + nivolumab Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1) | United States | bmsaccesssupport.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Revumenib Small-molecule menin inhibitor | United States | Not recorded | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Ribociclib Small-molecule CDK4/6 inhibitor | United Kingdom | Not recorded | NICE: recommended with aromatase inhibitor (TA496), fulvestrant (TA687), and adjuvant (2025) | Not recorded | Not recorded | source as of 2026-09-06 |
| Ribociclib Small-molecule CDK4/6 inhibitor | United States | novartis.com/us-en/patient-support | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Sacituzumab govitecan ADC | European Union | Not recorded | EMA approved; national reimbursement varies | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Sacituzumab govitecan ADC | United Kingdom | Not recorded | NICE: recommended for pretreated metastatic TNBC (TA819) and HR+/HER2- breast cancer after endocrine therapy and chemotherapy | Not recorded | Not recorded | source as of 2026-09-06 |
| Sacituzumab govitecan ADC | United States | gileadadvancingaccess.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Sacituzumab tirumotecan ADC | China | Not recorded | NMPA approved 2024; National Reimbursement Drug List inclusion from 2025 | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Sacituzumab tirumotecan ADC | United States | Not recorded | Investigational; not yet approved | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Satricabtagene autoleucel CAR-T (Claudin 18.2) | China | Not recorded | NMPA approved 2025-26; self-pay | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Selpercatinib Small-molecule kinase inhibitor (RET) | United Kingdom | Not recorded | NICE: recommended for RET-fusion NSCLC and thyroid cancers (TA911, TA742, TA760) | Not recorded | Not recorded | source as of 2026-09-06 |
| Selpercatinib Small-molecule kinase inhibitor (RET) | United States | lillycares.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Shield Blood-based colorectal cancer screening test | United States | Not recorded | Medicare covers Shield every 3 years for average-risk adults 45-85 (2024 NCD); commercial coverage expanding | $1,495 list price | Not recorded | source as of 2026-09-06 |
| Signatera Tumour-informed ctDNA MRD test | United States | Not recorded | Medicare covers colorectal (stage II-III and IV), muscle-invasive bladder, breast (neoadjuvant/adjuvant), ovarian, NSCLC and pan-cancer immunotherapy monitoring under MolDX; commercial coverage growing | ~$3,500 per test (Medicare rate, approximate) | Not recorded | source as of 2026-09-06 |
| Sonesitatug vedotin ADC | United States | Not recorded | Investigational (CLARITY-Gastric01) | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Sotorasib Small-molecule inhibitor (KRAS G12C) | United Kingdom | Not recorded | NICE: recommended via Cancer Drugs Fund for KRAS G12C NSCLC after platinum (TA781); later terminated then re-appraised | Not recorded | Not recorded | source as of 2026-09-06 |
| Sotorasib Small-molecule inhibitor (KRAS G12C) | United States | amgensupportplus.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Talazoparib Small-molecule PARP inhibitor | United Kingdom | Not recorded | NICE: recommended for gBRCA HER2-negative advanced breast cancer (TA952) and with enzalutamide in HRR-mutant mCRPC (2024) | Not recorded | Not recorded | source as of 2026-09-06 |
| Talazoparib Small-molecule PARP inhibitor | United States | pfizeroncologytogether.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Talimogene laherparepvec Oncolytic virus (HSV-1) | United Kingdom | Not recorded | NICE: recommended for unresectable melanoma when systemic immunotherapy is unsuitable (TA410) | Not recorded | Not recorded | source as of 2026-09-06 |
| Talimogene laherparepvec Oncolytic virus (HSV-1) | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Tarlatamab Bispecific T-cell engager (DLL3×CD3) | United Kingdom | Not recorded | NICE: appraisal for ES-SCLC after platinum in progress (2026) | Not recorded | Not recorded | source as of 2026-09-06 |
| Tarlatamab Bispecific T-cell engager (DLL3×CD3) | United States | amgensupportplus.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Tebentafusp ImmTAC (TCR×CD3 bispecific) | United Kingdom | Not recorded | NICE: recommended for HLA-A*02:01+ metastatic uveal melanoma (TA867) | Not recorded | Not recorded | source as of 2026-09-06 |
| Tebentafusp ImmTAC (TCR×CD3 bispecific) | United States | kimmtrak.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Teclistamab Bispecific T-cell engager (BCMA×CD3) | United Kingdom | Not recorded | NICE: recommended for relapsed/refractory myeloma after ≥3 therapies (TA1006) | Not recorded | Not recorded | source as of 2026-09-06 |
| Teclistamab Bispecific T-cell engager (BCMA×CD3) | United States | janssencarepath.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Telisotuzumab vedotin ADC | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Tilatamig samrotecan Bispecific ADC | United States | Not recorded | Investigational | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Tisotumab vedotin ADC | United Kingdom | Not recorded | NICE: appraisal for recurrent cervical cancer (2025-26) | Not recorded | Not recorded | source as of 2026-09-06 |
| Tisotumab vedotin ADC | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Trastuzumab Monoclonal antibody (anti-HER2) | United Kingdom | Not recorded | NICE: standard of care; biosimilars widely used | Not recorded | Not recorded | source as of 2026-09-06 |
| Trastuzumab Monoclonal antibody (anti-HER2) | United States | genentech-access.com | Medicare Part B; five biosimilars available since 2019, roughly 15-35% below reference price | Not recorded | Yes | source as of 2026-09-06 |
| Trastuzumab deruxtecan ADC | Japan | Not recorded | NHI listed; approved in HER2+ breast and gastric cancer since 2020 | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Trastuzumab deruxtecan ADC | United Kingdom | Not recorded | NICE: recommended in HER2+ breast cancer after ≥1 anti-HER2 regimen (TA862) and HER2-low breast cancer (TA1090); HER2-mutant NSCLC via CDF | Not recorded | Not recorded | source as of 2026-09-06 |
| Trastuzumab deruxtecan ADC | United States | enhertu4u.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Trastuzumab emtansine ADC | United Kingdom | Not recorded | NICE: recommended for residual invasive disease after neoadjuvant therapy (TA632) and HER2+ metastatic disease (TA458) | Not recorded | Not recorded | source as of 2026-09-06 |
| Trastuzumab emtansine ADC | United States | genentech-access.com | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Tucatinib Small-molecule kinase inhibitor (HER2) | United Kingdom | Not recorded | NICE: recommended with trastuzumab and capecitabine for HER2+ breast cancer after ≥2 anti-HER2 regimens (TA786) | Not recorded | Not recorded | source as of 2026-09-06 |
| Tucatinib Small-molecule kinase inhibitor (HER2) | United States | pfizeroncologytogether.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Venetoclax Small-molecule BCL-2 inhibitor | United Kingdom | Not recorded | NICE: recommended in CLL (TA487, TA561, TA663) and AML with azacitidine (TA765) | Not recorded | Not recorded | source as of 2026-09-06 |
| Venetoclax Small-molecule BCL-2 inhibitor | United States | venclexta.com/support | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Vepdegestrant PROTAC oestrogen receptor degrader | United States | pfizeroncologytogether.com | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Vorasidenib Small-molecule IDH1/2 inhibitor | United Kingdom | Not recorded | NICE: recommended for grade 2 IDH-mutant glioma after surgery (2025) | Not recorded | Not recorded | source as of 2026-09-06 |
| Vorasidenib Small-molecule IDH1/2 inhibitor | United States | Not recorded | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Vusolimogene oderparepvec Oncolytic virus (HSV-1) | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Zanidatamab Biparatopic bispecific antibody (HER2) | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Zenocutuzumab Bispecific antibody (HER2×HER3) | United States | Not recorded | Medicare Part B (physician-administered); commercial plans per formulary | Not recorded | Not recorded | source as of 2026-09-06 |
| Zidesamtinib Small-molecule kinase inhibitor (ROS1) | United States | Not recorded | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
| Zilovertamab vedotin ADC | United States | Not recorded | Investigational | Not recorded | Not recorded | Not recorded as of 2026-09-06 |
| Zongertinib Small-molecule kinase inhibitor (HER2) | United States | Not recorded | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | Not recorded | Not recorded | source as of 2026-09-06 |
National schemes and charities: all countries
Figures only where the linked page states them.Who: Anyone with Medicare drug coverage (a Part D plan or a Medicare Advantage plan with drug cover) taking oral cancer drugs and other pharmacy-dispensed medicines.
What: Since 2025 there is a yearly limit on what you pay out of pocket for covered Part D drugs; once you reach it you pay nothing more for covered drugs that year. Medicare publishes the current year's amount. You can also spread payments over the year through the Medicare Prescription Payment Plan.
- Check that the drug is on your plan's formulary; infused drugs given in a clinic are usually Part B, not Part D, and the cap does not apply to them.
- Ask your plan about the Medicare Prescription Payment Plan if a large bill lands early in the year.
- Compare plans each autumn during open enrolment; formularies and tiers change.
Source: Medicare.gov: costs for Medicare drug coverage · checked 2026-09-09
Who: People with Medicare who have limited income and resources.
What: Pays the Part D premium and deductible and reduces copayments for covered drugs; there is no late-enrolment penalty while you receive it.
- Apply through Social Security online or by phone; people on Medicaid, Supplemental Security Income or a Medicare Savings Program qualify automatically.
- Once approved, tell your Part D plan so copayments are adjusted.
Source: Medicare.gov: help with drug costs · checked 2026-09-09
Who: Patients treated at safety-net hospitals, community health centres and other covered entities.
What: Lets those providers buy outpatient drugs at discounted prices; many use the savings to fund free or reduced-cost medicines and services for uninsured and under-insured patients. The discount does not flow to you automatically, so ask.
- Ask the hospital's financial counsellor or pharmacy whether it is a 340B covered entity and what patient discount or charity programme it runs.
- Bring proof of income and insurance status.
Source: HRSA: Office of Pharmacy Affairs (340B) · checked 2026-09-09
Who: Uninsured or under-insured patients (free-drug programmes) and commercially insured patients (copay cards). Copay cards cannot be used with Medicare or Medicaid.
What: Free or reduced-cost supply of a branded drug, or a card that covers the copay. Each product has its own programme; the manufacturer links in the table above go straight to them.
- Find the programme for your drug in the table above, or search NeedyMeds by drug name.
- Your clinic's financial navigator or the infusion pharmacy usually enrols you; income documents and a prescription are needed.
- Re-enrol each year and whenever your insurance changes.
Source: NeedyMeds programme directory · checked 2026-09-09
Who: Insured patients with a qualifying diagnosis and household income under the programme's limit; funds open and close by disease.
What: Direct payment of copays, coinsurance and deductibles for treatment of the covered diagnosis.
- Check whether the fund for your cancer is open on the Co-Pay Relief site.
- Apply online or by phone with your diagnosis, insurance and income details; your provider can bill the fund directly.
Source: PAF Co-Pay Relief · checked 2026-09-09
Who: People in active cancer treatment who meet income guidelines.
What: Limited grants for treatment-related costs such as transport, home care and child care, plus copay assistance funds for some diagnoses, and free counselling from oncology social workers.
- Call or apply online; an oncology social worker screens eligibility and can point to other funds.
Source: CancerCare: financial assistance · checked 2026-09-09
Who: Insured patients whose fund for a specific disease is open and whose income is under the fund's limit.
What: Grants toward copays, premiums and deductibles for the covered disease.
- Search the open funds list for your cancer type.
- Apply online; grants are paid to the pharmacy or provider.
Source: HealthWell Foundation · checked 2026-09-09
Who: Insured patients with a blood cancer covered by an open fund.
What: Help with insurance premiums and copays for treatment of the covered blood cancer.
- Check the open diagnoses on the LLS site and apply online or through an LLS information specialist.
Source: LLS Co-Pay Assistance Program · checked 2026-09-09
Who: Patients who need a ride to treatment and cannot drive themselves.
What: Free rides to and from treatment from trained volunteer drivers, where the programme operates.
- Call the ACS helpline or request a ride online a few days in advance.
Source: ACS Road To Recovery · checked 2026-09-09
Who: Patients and a caregiver travelling away from home for treatment.
What: Free lodging near treatment centres in the cities where a Hope Lodge operates.
- Ask your treatment centre's social worker to refer you, or contact the Lodge directly; availability varies.
Source: ACS Hope Lodge · checked 2026-09-09
Who: Anyone in England being treated for cancer, its effects, or the effects of treatment. Prescriptions are already free in Scotland, Wales and Northern Ireland.
What: All NHS prescriptions free of charge for five years, renewable, not only the cancer drugs.
- Ask your GP surgery or hospital for form FP92A; a clinician signs it.
- The certificate arrives from the NHS Business Services Authority; tick the exemption box on the prescription form and show the certificate if asked.
Source: NHSBSA: medical exemption certificates · checked 2026-09-09
Who: People living with cancer on a low income and with limited savings.
What: A one-off payment towards costs such as heating, travel to hospital, clothing or household items.
- A health or social care professional (for example a Macmillan nurse or hospital social worker) applies with you.
- Macmillan's support line can check eligibility and connect you with a professional to apply.
Source: Macmillan Grants · checked 2026-09-09
Who: People aged 16 to State Pension age in England and Wales whose illness or treatment affects daily living or mobility; Scotland has Adult Disability Payment.
What: A regular, non-means-tested payment. People who are terminally ill can claim under special rules with a faster decision and no assessment.
- Start the claim by phone or online on GOV.UK.
- Ask your clinical team for the SR1 form if you may qualify under the special rules for end of life.
- Macmillan and Citizens Advice can help fill in the forms.
Source: GOV.UK: Personal Independence Payment · checked 2026-09-09
Who: People over State Pension age who need help with personal care or supervision because of illness.
What: A regular, non-means-tested payment at one of two rates; special rules apply for terminal illness.
- Claim by post using the form on GOV.UK or by phone; the special-rules route uses the SR1 form from your clinician.
Source: GOV.UK: Attendance Allowance · checked 2026-09-09
Who: NHS patients in England whose oncologist recommends a drug that NICE has placed in the Fund while more evidence is collected.
What: Interim NHS funding for promising drugs that are not yet in routine commissioning; your clinician applies, not you. The 'What the NHS offers' page lists which products are in the Fund.
- Ask your oncologist whether the treatment is in the CDF and whether you meet the treatment criteria.
- The hospital submits the application; the drug is then supplied free on the NHS.
Source: NHS England: Cancer Drugs Fund · checked 2026-09-09
Who: Anyone with cancer, and their family and friends, near a Maggie's centre.
What: Free practical, emotional and financial support, including benefits advice from trained advisers, without an appointment.
- Walk in to a centre, most of which sit next to NHS cancer hospitals, or contact one online.
Source: Maggie's · checked 2026-09-09
Who: People insured in an EU or EEA country who want treatment or a consultation in another member state.
What: Reimbursement by your home insurer up to what the same care would have cost at home; prior authorisation may be required for hospital stays and costly treatments. National schemes for cancer drugs and copayments differ by country, so ask your national contact point.
- Find your national contact point through the Your Europe portal.
- Ask whether prior authorisation is needed before travelling.
- Keep invoices and reports for reimbursement.
Source: Directive 2011/24/EU · checked 2026-09-09
Who: Anyone with a Medicare card filling PBS-listed prescriptions, including most oral cancer drugs; concession card holders pay a lower co-payment.
What: Subsidised medicines with a fixed co-payment per script. Once a family's spending reaches the yearly Safety Net threshold, scripts for the rest of the year are cheaper or free for concession holders. Services Australia publishes the current thresholds.
- Ask one pharmacy to keep a Prescription Record Form, or ask each pharmacy to record your scripts, so spending is tracked for the Safety Net.
- Apply for a Safety Net card when the threshold is reached.
Source: Services Australia: PBS Safety Net thresholds · checked 2026-09-09
Who: Anyone with high out-of-hospital costs, for example specialist consultations, scans and radiotherapy given as an outpatient.
What: Once your gap payments in a calendar year pass a threshold, Medicare pays a higher share of further out-of-hospital costs for the rest of the year.
- Register as a family or couple with Services Australia so costs are pooled.
- Services Australia tracks the total from claims automatically.
Source: Services Australia: Medicare Safety Nets · checked 2026-09-09
Who: People affected by cancer in any state or territory.
What: Financial counselling, legal and workplace advice through the Pro Bono Program, transport and accommodation help for people travelling to treatment, and referral to state patient travel assistance schemes.
- Call 13 11 20 or contact your state Cancer Council; a nurse or counsellor screens and refers you.
Source: Cancer Council: practical and financial assistance · checked 2026-09-09
Who: Everyone enrolled in Japanese public health insurance, which is compulsory for residents.
What: A monthly ceiling on what you pay for insured medical care, set by age and income band; the insurer reimburses anything above it, and the ceiling falls further after several high-cost months in a year.
- Ask your insurer for a Certificate of Eligibility for Ceiling-Amount Application (gendogaku tekiyou ninteishou) before treatment so the hospital bills you only up to the ceiling.
- Without the certificate, pay and then claim reimbursement from the insurer.
Source: Ministry of Health, Labour and Welfare (Japanese) · checked 2026-09-09
Who: People covered by basic medical insurance, which covers most residents.
What: Cancer drugs added to the list after national price negotiation are reimbursed at a share set by the provincial scheme; drugs not on the list are largely self-pay. The list is updated each year, and many new targeted drugs and immunotherapies have been added through negotiation.
- Ask the hospital pharmacy whether your drug is on the current NRDL and what the local reimbursement share is.
- Some hospitals and provinces also run supplementary insurance (huiminbao) and charity supply programmes for drugs not yet listed; ask the social worker or the manufacturer.
Source: National Healthcare Security Administration · checked 2026-09-09
Who: Residents with a provincial health card. Coverage rules differ by province: hospital-administered drugs are covered everywhere, while take-home oral cancer drugs are covered fully in some provinces and through public drug plans with deductibles in others.
What: Public funding of cancer drugs recommended by Canada's Drug Agency and negotiated by the pan-Canadian Pharmaceutical Alliance, then listed by each province.
- Ask your cancer centre's drug access navigator which programme covers your drug where you live.
- If a take-home drug is not covered, ask about the provincial drug plan, private insurance and the manufacturer's patient support programme.
Source: pan-Canadian Pharmaceutical Alliance · checked 2026-09-09
Who: People affected by cancer anywhere in Canada.
What: Guidance on income supports, tax credits and drug coverage, plus travel and lodging programmes near treatment centres.
- Call the Cancer Information Helpline or use the community services locator on the site.
Source: Canadian Cancer Society: financial help · checked 2026-09-09
Patient organisations with financial and practical help
A childhood-cancer charity started by a four-year-old patient's lemonade stand that now funds hundreds of grants and runs an open-science data lab for paediatric cancer genomics.
alexslemonade.orgThe American Cancer Society is the largest US cancer charity: the source of the widely quoted annual US cancer statistics, screening recommendations that differ from the USPSTF in places, and plain-language patient guides for every cancer.
cancer.orgThe Colorectal Cancer Alliance is the largest US colorectal cancer patient organisation, focused on screening uptake from age 45, young-onset disease and connecting patients with biomarker-matched trials.
colorectalcancer.orgThe Leukemia & Lymphoma Society is the main US blood-cancer charity, unusual for running its own precision-medicine trials (Beat AML, PedAL) and investing directly in biotech, alongside co-pay assistance and one-to-one information specialists.
lls.orgLUNGevity is the largest US lung cancer charity, focused on making sure every patient gets comprehensive biomarker testing and access to targeted therapy and trials, with a screening-advocacy partner in GO2.
lungevity.orgThe Lymphoma Research Foundation is the largest US lymphoma-specific charity, with plain-language guides for over 20 lymphoma subtypes and a research programme focused on mantle cell and adolescent/young adult lymphoma.
lymphoma.orgA melanoma research funder created in 2007 by the Milken family that backed early immunotherapy and targeted-therapy work and now focuses on rare melanoma subtypes and resistance.
curemelanoma.orgA myeloma foundation that built the most important open genomic dataset in the disease (CoMMpass) and funded much of the science behind today's therapies; also a patient support and navigation resource.
themmrf.orgThe National Brain Tumor Society is the largest US brain tumour nonprofit, notable for helping create GBM AGILE, the adaptive platform trial that tests many glioblastoma drugs at once, and for its advocacy on FDA endpoints for brain tumours.
braintumor.orgThe Ovarian Cancer Research Alliance is the largest US ovarian cancer organisation, born from the merger of research and patient-support charities; it funds research and campaigns for universal genetic testing and prevention by salpingectomy given that screening does not work.
ocrahope.orgPanCAN is the leading pancreatic cancer patient organisation; it pioneered free tumour molecular profiling for patients (Know Your Tumor) and runs an adaptive platform trial for a disease with few options.
pancan.orgMichael Milken's prostate cancer foundation, which funded the science behind abiraterone, enzalutamide and PSMA therapy and runs a precision-oncology network in US veterans' hospitals.
pcf.orgA head-shaving fundraiser that became the largest charitable funder of children's cancer research in the US, underwriting much of the cooperative-group trial infrastructure that treats most American children with cancer.
stbaldricks.orgSusan G. Komen is the best-known breast cancer charity, a major funder of research and a large provider of patient navigation and financial assistance, with a patient-driven research registry that shares data for metastatic breast cancer research.
komen.orgMost are US-based and disease-specific; many run copay funds, travel grants or navigation lines. In the UK, Macmillan and Maggie's are the first call; in Australia, Cancer Council.